Skip to content

Publications and Presentations

Published data and presentations from medical conferences for Karyopharm’s investigational drug candidates

This page is intended to provide scientific information to scientific research professionals. XPOVIO (selinexor) has only been approved by the United States Food and Drug Administration (FDA) for the following indications:

• In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

• For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

Conditional Marketing Authorization from the European Commission granted on March 29, 2021: NEXPOVIO is indicated in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

On May 26, 2021 the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization for NEXPOVIO® (selinexor), in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Karyopharm’s other drug candidates, including selinexor in additional indications, are investigational medicines and have not been approved by FDA, Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.  

Multiple Myeloma

Posters and Presentations
  1. Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Patients with Multiple Myeloma (MM) After 1-3 Prior Therapies: Initial Results of the Phase 3 BOSTON Study
  2. Selinexor, Daratumumab, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM)
  3. Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Heavily Pretreated Multiple Myeloma
  4. Oral Selinexor, Pomalidomide, and Dexamethasone (XPd) at Recommended Phase 2 Dose in Relapsed Refractory Multiple Myeloma
  5. Selinexor, Lenalidomide, and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma
  6. Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
  7. Results of the Pivotal STORM Study (Part 2): Deep and Durable Responses with Oral Selinexor plus Low Dose Dexamethasone in Patients with Penta-Exposed and Triple Class Refractory MM
  8. Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated With Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies
  9. Selinexor Combined with Low Dose Bortezomib and Dexamethasone (SVd) Induces a High Response Rate in Patients with Relapsed or Refractory Multiple Myeloma (MM)
  10. Improved Overall Survival (OS) with Oral Selinexor Plus Low Dose Dexamethasone (Sd) in Patients with Triple Class Refractory Multiple Myeloma (TCR-MM) Compared to FLATIRON – Real World Evidence
  11. Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selienxor, Bortezomib, and Dexamethasone in Comparison with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis From the BOSTON Study
  12. Once Weekly Selinexor, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses From the Phase 3 BOSTON Study
  13. Impact of Prior Therapies on the Safety and Efficacy of Once-Weekly Selinexor, Bortezomib, and Dexamethasone Compared With Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the BOSTON Study
  14. Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 BOSTON Study

Solid Tumors

Posters and Presentations
  1. SEAL: Phase 3, Randomized, Double Blind, Cross-Over, Study of Selinexor versus Placebo in Advanced Unresectable DeDifferentiated Liposarcoma (DDLS)
  2. SIENDO/ENGOT-EN5: A randomized phase 3 trial of maintenance with selinexor/placebo after combination chemotherapy in patients with advanced or recurrent endometrial cancer
  3. Final Results of the KING trial: Phase 2 Study of Efficacy, Safety, and Intratumoral Pharmacokinetics of Selinexor (KPT-330) Monotherapy in Recurrent Glioblastoma
  4. Phase 2 Results of Selinexor in Advanced DeDifferentiated (DDLS) Liposarcoma (SEAL) Study: A Phase 2/3, Randomized, Double Blind, Placebo Controlled Cross-Over Study
  5. Results of a Phase II Trial of Selinexor, in Patients with Gynaecological Cancers
  6. Phase 1b study to evaluate the safety of selinexor in combination with pembrolizumab in patients with advanced malignancies – The melanoma experience
  7. Selinexor in combination with carboplatin and paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study
  8. Randomized Phase III Study of Maintenance Selinexor vs Placebo in Endometrial Cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of Subgroup Analysis and Molecular Classification
  9. SGO: Prospective double-blind, randomized phase III ENGOTEN5/ GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
  10. ESMO: Prospective double-blind, randomized phase III ENGOTEN5/ GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
I agree to the storing and processing of my personal data by Karyopharm as described in the Privacy Policy and to the Terms of Use . I agree to receive communications from Karyopharm and understand that I can unsubscribe at any time.